3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
18
Gastrointestinal
18
Breast
15
Other
9
Gynecologic
8
Other hematologic neoplasm
4
Lymphoid
4
Dermatologic
4
Thoracic
3
Plasma cell
3
CNS
3
Head & Neck
2
Sarcoma
1
Other solid neoplasm
1
NET
1
Myeloid
1
Endocrine
1
Conditions
Neuroendocrine Tumors
1
Interventions
lutetium Lu 177 dotatate
32
Everolimus
19
Magnetic Resonance Spectroscopy
14
gallium Ga 68 dotatate
12
Temozolomide
12
Nivolumab
11
Capecitabine
10
pembrolizumab
9
lanreotide
9
cabozantinib
8
Positron Emission Tomography Computed Tomography
8
177Lu-octreotide, DOTA(0)-Tyr(3)-
8
Ga(III)-DOTATOC
7
3-Iodobenzylguanidine
7
Somatostatin
6
Octreotide
6
Lutetium-177
6
Carboplatin
6
90Y-octreotide, DOTA-Tyr(3)-
6
telotristat ethyl
5
surufatinib
5
lenvatinib
5
Ipilimumab
5
Fluorodeoxyglucose F18
5
pasireotide
4
copper dotatate CU-64
4
avelumab
4
Single Photon Emission Computed Tomography Computed Tomography
4
Positron-Emission Tomography
4
Bevacizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Diet Therapy
×
NET
×
Clear all
NCT02481804
2024-05-06
DIVIT-pilot
University Medical Center Groningen
Phase NA
Completed
15 enrolled